AbbVie Raises Full-Year Outlook After Q3 Beat as Skyrizi Pipeline Expands
AbbVie beat Q3 2026 estimates and raised its full-year outlook while advancing Skyrizi combinations and reporting positive CERVINO results.
AstraZeneca ADR Jumps 7% After Q3 Beat as Tagrisso and Baxfendy Drive Momentum
AstraZeneca's Nasdaq-listed ADR rose 7% after a Q3 beat, with Tagrisso sales and respiratory pipeline progress supporting the outlook.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Nasdaq Suffers Worst Month Since March 2025 as AI Costs and Fed Signals Pressure Tech
The Nasdaq endured its worst month since March 2025 as AI spending concerns and hawkish Fed commentary pressured technol…
Global Payments Jumps as CD&R Reportedly Pursues Takeover
Global Payments shares surged after Seeking Alpha reported that CD&R is pursuing a takeover, putting payments-sector M&A…
Inovio Stock Surges After FDA Clears First Product as Precigen Shares Sink
Inovio's first FDA approval triggered a sharp stock reaction, while Precigen shares fell as investors reassessed the RRP…
Marvell-Lumentum Deal Reportedly Set to Avoid Large Premium
A muted takeover premium could temper Lumentum shareholder enthusiasm and reshape merger-arbitrage expectations around t…
Acumen Pharmaceuticals Downgraded After Sabirnetug Fails Phase 2 Alzheimer’s Trial
Acumen’s ABOS faces a major biotech catalyst after sabirnetug missed key Phase 2 endpoints, prompting a Stifel downgrade…
Regeneron Jumps 12% as Dupixent Royalties and Eylea HD Fuel Earnings Beat
Regeneron surged 12% after an earnings beat, powered by Dupixent royalties, Eylea HD sales, buybacks, cash and a Decembe…
FDA Delays Mitapivat Sickle Cell Decision Until February 2027
The FDA extended its mitapivat review to February 2027, pushing a key regulatory and commercial catalyst further into th…
Sun Pharma’s Ilumya Wins FDA Approval for Psoriatic Arthritis
FDA approval for Ilumya in active psoriatic arthritis broadens Sun Pharma’s U.S. immunology opportunity while intensifyi…
NRx Pharmaceuticals Shares Jump 15% After Early FDA Approval for Preservative-Free Ketamine
NRx Pharmaceuticals won early FDA approval for preservative-free ketamine, sending NRXP shares approximately 15% higher …